Bridgeway Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Bridgeway Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-83,800	Closed	-$482K	–	1300
2021 Q2	$482K	Buy	83,800 +20,800	+33%	+$107K	0.01%	1075
2021 Q1	$290K	Sell	63,000 -26,500	-30%	-$105K	0.01%	1231
2020 Q4	$299K	Sell	89,500 -14,900	-14%	-$50.1K	0.01%	1120
2020 Q3	$310K	Buy	104,400 +63,000	+152%	+$246K	0.01%	1052
2020 Q2	$191K	Hold	41,400	–	–	﹤0.01%	1159
2020 Q1	$159K	Buy	+41,400	New	+$170K	﹤0.01%	1115

Other funds holding CPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bridgeway Capital Management's CPRX Position: Q3 2021 in Review

Bridgeway Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2021, closing a stake of 83,800 shares — an estimated $482K sold.

Bridgeway Capital Management first reported a position in CPRX in Q1 2020 and held it in 6 quarters. The position peaked at $482K in Q2 2021. 144 funds tracked by Wall St. Rank hold CPRX as of Q3 2021.

Bridgeway Capital Management reported no remaining Catalyst Pharmaceutical position as of Q3 2021 after selling out during the quarter.
Bridgeway Capital Management sold 83,800 Catalyst Pharmaceutical shares in Q3 2021, an estimated $482K.
Bridgeway Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2020 and held it in 6 quarters.
Bridgeway Capital Management's Catalyst Pharmaceutical position peaked at $482K in Q2 2021.
144 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2021.

Based on Bridgeway Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.